Skip to main content
. 2019 Dec 30;295(6):1565–1574. doi: 10.1074/jbc.RA119.011857

Figure 3.

Figure 3.

Structure and in vitro profiling of lead compound and other analogs against IRAK-4 and TAK1. a, structures of HS-243 IRAK-1/4 inhibitor, HS-242 dual TAK1/IRAK-4 inhibitor, HS-206 (takinib) TAK1 inhibitor, and HS-238 mixed TAK1/IRAK-4 inhibitor. b–e, data show kinase inhibition generated for each indicated analog against purified IRAK-4 and TAK1. The data points represent means ± S.E. (n = 2).